New hope for transplant patients: targeted combo aims to beat rare cancer
NCT ID NCT06040320
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare blood cancer that can occur after organ or stem cell transplants. The goal is to see if this combo is safe and works better than current options, possibly avoiding the need for strong chemotherapy. About 12 adults who have not been treated before will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin (Polivy) and rituximab (Rituxan), with optional CHP chemotherapy
What this could lead to
If successful, this combination could offer a more effective and less toxic first treatment for PTLD, potentially sparing patients from harsh chemotherapy.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply broadly. The drug combination may still cause significant side effects or fail to improve response rates.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.